Executive Committee: Bolt Biotherapeutics, Inc.

Manager
Positions heldSince
William Quinn

William Quinn

53 year

Chief Executive Officer 14/05/2024
Director of Finance/CFO 30/04/2020
President 14/05/2024
Grant Yonehiro

Grant Yonehiro

60 year

Chief Operating Officer 14/05/2024
Wesley Burwell

Wesley Burwell

Human Resources Officer 31/12/2020
Sarah Nemec

Sarah Nemec

49 year

Comptroller/Controller/Auditor 14/05/2024

Composition of the Board of Directors: Bolt Biotherapeutics, Inc.

Director
CommitteesSince
Brian O'Callaghan

Brian O'Callaghan

54 year

Audit Committee 03/09/2024
Compensation Committee Chair 03/09/2024
Kathy LaPorte

Kathy LaPorte

63 year

Audit Committee Chair 24/03/2024
Compensation Committee 30/11/2020
Audit Committee 13/02/2024
Governance Committee 24/03/2024
Nominating Committee 24/03/2024
Compensation Committee Chair 30/09/2021
Jakob Dupont

Jakob Dupont

60 year

Audit Committee 30/12/2024
Compensation Committee
Nominating Committee 30/12/2024
Governance Committee 30/12/2024
Laura Berner

Laura Berner

49 year

Compensation Committee 13/12/2022
Compensation Committee Chair 13/12/2022
Nominating Committee Chair 13/12/2022
Nicole Onetto

Nicole Onetto

71 year

Compensation Committee
Governance Committee 13/12/2021
Nominating Committee 13/12/2021
William Quinn

William Quinn

53 year

Director/Board Member 14/05/2024

Former Officers and Directors: Bolt Biotherapeutics, Inc.

Insider
Positions held
SinceUntil
Dawn Colburn
Dawn Colburn
Chief Tech/Sci/R&D Officer 31/07/2023 31/12/2024
Mahendra Shah
Mahendra Shah
Director/Board Member 31/08/2016 30/12/2024
Independent Dir/Board Member 31/08/2016 30/12/2024
James Healy
James Healy
Director/Board Member 31/12/2020 02/09/2024
Independent Dir/Board Member 31/12/2020 02/09/2024
Frank Lee
Frank Lee
Director/Board Member 16/11/2021 02/09/2024
Independent Dir/Board Member 16/11/2021 02/09/2024
John Tomaro
John Tomaro
Chief Tech/Sci/R&D Officer 31/12/2021 30/06/2024
Richard Miller
Richard Miller
Director/Board Member 30/06/2017 11/06/2024
Independent Dir/Board Member 30/06/2017 11/06/2024
Edgar Engleman
Edgar Engleman
Director/Board Member 21/01/2015 14/05/2024
Founder 21/01/2015 14/05/2024
Independent Dir/Board Member 21/01/2015 14/05/2024
Edith Perez
Edith Perez
Chief Tech/Sci/R&D Officer 31/03/2020 14/05/2024
Randall Schatzman
Randall Schatzman
Director/Board Member 30/06/2019 14/05/2024
Chief Executive Officer 30/06/2019 14/05/2024
David Dornan
David Dornan
Chief Tech/Sci/R&D Officer - 10/03/2022
Corporate Officer/Principal 28/02/2019 -
Ashish Khanna
Ashish Khanna
Director/Board Member 30/06/2018 12/12/2021
Independent Dir/Board Member 30/06/2018 12/12/2021
Peter Moldt
Peter Moldt
Director/Board Member 31/08/2016 -
Chairman 31/08/2016 14/11/2021
Independent Dir/Board Member 31/08/2016 14/11/2021
Jason Pitts
Jason Pitts
Director/Board Member 30/06/2020 31/12/2020
Karen L. Bergman
Karen L. Bergman
Investor Relations Contact 31/12/2020 -
Public Communications Contact 31/12/2020 -
Laurie C. Torres
Laurie C. Torres
Human Resources Officer 31/12/2019 -
Yu Tai
Yu Tai
General Counsel - -
Peter Bisgaard
Peter Bisgaard
Director/Board Member - -
Priti Hegde
Priti Hegde
Chief Tech/Sci/R&D Officer - -
Reiner Laus
Reiner Laus
Chief Executive Officer - -
President - -

Age distribution of managers

Parity Men Women

Male6
Female3

Of which Executive Committee

Male3
Female1

Of which Directors

Male4
Female2

Revisions

Revenue revisions (1 year)
-
Revenue revisions (4 months)
-
Revenue revisions (1 month)
-
EPS revisions (1 year)
-
EPS revisions (4 months)
-
ESG MSCI
-
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
52
More about the company

Departures of Key Persons

Reiner Laus
-
Reiner Laus

Chief Executive Officer

Peter Moldt
-
Peter Moldt

Chairman

31/08/2016 14/11/2021

Randall Schatzman
-
Randall Schatzman

Chief Executive Officer

30/06/2019 14/05/2024